The live attenuated bovine viral diarrhea virus components of a multi-valent vaccine confer protection against fetal infection.
Fetal infection with bovine virus diarrhea virus (BVDV) causes severe economic loss and virus spread in cattle. This study investigated the ability of modified live BVDV I and II components of a commercially available modified live virus (MLV) vaccine (Breed-Back FP 10, Boehringer Ingelheim Vetmedica Inc.) to prevent fetal infection and abortion, and therefore the birth of persistently infected animals. Heifers immunized with vaccine 4-8 weeks before insemination showed no adverse effects. All vaccinated animals had seroconverted to BVDV 4 weeks after immunization. Pregnant heifers were divided into two vaccination and two control groups and challenged with type I or II BVDV on days 60-90 of gestation. Seroconversion, clinical signs, immunosuppression, viremia, mortality, abortion rate, and fetal infection were studied. Post-challenge, 6/11 (type I challenged) and 8/11 (type II challenged) vaccinated heifers were free from clinical signs of BVD. Post-challenge clinical signs noted in the vaccinated groups were mild to moderate, while all unvaccinated controls had clinical signs ranging from moderate to severe. Viremia was not detected post-challenge in any of the vaccinated heifers. However, 100% of the controls were BVDV viremic on at least 1 day post-challenge. One of 22 vaccinated heifers had transient leukopenia, whereas 2/8 and 6/7 unvaccinated heifers in control groups I and II, respectively, had transient leukopenia. Type II BVDV infection led to abortion or death in 86% of unvaccinated heifers. The corresponding vaccinated group showed no deaths or abortions. All control group fetuses were infected with BVDV. The test vaccine gave 91% (type I BVDV challenged) and 100% (type II BVDV challenged) protection from fetal infection. This vaccine is safe and effective against fetal infection, abortion (type II BVDV) and the birth of persistently infected animals.
D000034:Abortion, Veterinary / Q000517:prevention & control / Q000821:virology; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis / Q000097:blood; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000517:prevention & control* / Q000635:transmission; D002417:Cattle; D030241:Diarrhea Virus 1, Bovine Viral / Q000276:immunology; D030242:Diarrhea Virus 2, Bovine Viral / Q000276:immunology; D001908:Diarrhea Viruses, Bovine Viral / Q000276:immunology*; D005260:Female; D005315:Fetal Diseases / Q000517:prevention & control / Q000662:veterinary*; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control / Q000662:veterinary*; D007970:Leukopenia / Q000517:prevention & control / Q000662:veterinary; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control / Q000662:veterinary*; D011897:Random Allocation; D016896:Treatment Outcome; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage / Q000276:immunology; D014766:Viremia / Q000453:epidemiology / Q000517:prevention & control / Q000662:veterinary
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D017778:Vaccines, Combined; D014765:Viral Vaccines